Summary
Boston Scientific Corporation (BSX) filed an 8-K report on May 8, 2023, detailing the outcomes of its 2023 Annual Meeting of Stockholders held on May 4, 2023. The meeting, conducted virtually, saw all nine director nominees re-elected for one-year terms, indicating strong shareholder confidence in the current board leadership. Key resolutions also passed with significant shareholder approval, including the advisory vote on executive compensation, often referred to as "say-on-pay," and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year 2023. Furthermore, shareholders overwhelmingly favored an annual frequency for future advisory votes on executive compensation, reinforcing a preference for regular oversight of management pay.
Key Highlights
- 1All nine director nominees were successfully elected to the Board of Directors, each for a one-year term.
- 2Shareholders overwhelmingly approved the "say-on-pay" proposal, endorsing the compensation of Named Executive Officers.
- 3A strong majority of shareholders voted for an annual frequency for future advisory votes on executive compensation.
- 4The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2023 was ratified by shareholders.
- 5The virtual format of the Annual Meeting aimed to provide broad accessibility to shareholders.